Dow Surges 150 Points; US Economy Grows At 2.1% Pace In Q2
Portfolio Pulse from Lisa Levin
US stocks traded higher with the Dow Jones gaining around 150 points. The US economy expanded at an annualized pace of 2.1% in Q2 2023. NanoVibronix, AgileThought, and Digital Brands Group saw significant stock increases, while Outlook Therapeutics, TD Holdings, and FibroGen experienced notable drops. The US trade deficit in goods widened to $91.2 billion in July.
August 30, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AgileThought shares increased by 66% after falling 17% on Tuesday.
Despite a 17% drop on Tuesday, AgileThought's shares have rebounded significantly, indicating a potential recovery in investor confidence.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Digital Brands Group shares were up 54% after a 1-for-25 reverse stock split.
The 1-for-25 reverse stock split has likely led to a surge in Digital Brands Group's stock price due to a decrease in the number of shares available.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
NanoVibronix shares shot up 126% after reporting positive outcomes from a UroShield study.
The positive outcomes from the UroShield study have significantly boosted investor confidence, leading to a surge in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
FibroGen shares fell 22% after announcing topline data from the Phase 3 LELANTOS-2 trial.
The announcement of topline data from the Phase 3 LELANTOS-2 trial has likely disappointed investors, leading to a drop in FibroGen's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
NEGATIVE IMPACT
TD Holdings shares were down 25% after dipping 72% on Tuesday.
TD Holdings' shares have continued to fall, indicating a sustained lack of investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 85
NEGATIVE IMPACT
Outlook Therapeutics shares dropped 81% after receiving an FDA complete response letter regarding ONS-5010.
The FDA's complete response letter regarding ONS-5010 has negatively impacted investor confidence, leading to a significant drop in Outlook Therapeutics' stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 95